Methods of providing neuroprotection
Cognitive impairments are treated and cognition is improved with an amphetamine compound. In one embodiment, the method includes administering an 1-amphetamine compound. In another embodiment, the method includes administering an 1-methamphetamine compound.
1 . A method of providing neuroprotection in a human, comprising the step of administering a composition that includes at least one member selected from the group consisting of 1-amphetamine and 1-methamphetamine to the human, wherein the 1-amphetamine is at least 60 mole percent 1-amphetamine relative to the total 1-amphetamine and 1-methamphetamine components of the composition or wherein the 1-methamphetamine is at least 85 mole percent 1-methamphetamine relative to the total 1-methamphetamine and 1-amphetamine components of the composition.
2 . The method of claim 1 , wherein the composition administered to the human includes 1-amphetamine.
3 . The method of claim 2 , wherein the composition includes at least about 80 mole percent 1-amphetamine relative to a total amphetamine content of the composition.
4 . The method of claim 1 , wherein the composition administered to the human includes 1-methamphetamine.
5 . The method of claim 4 , wherein the composition includes at least about 90 mole percent 1-methamphetamine relative to a total methamphetamine content of the composition.
6 . The method of claim 1 , wherein the human has a stroke subsequent to the administration of the composition.
7 . The method of claim 1 , wherein the human has a traumatic brain injury subsequent to the administration of the composition.
8 . The method of claim 1 , wherein the human has multiple sclerosis subsequent to the administration of the composition.
9 . The method of claim 1 , wherein an impairment in at least one member selected from the group consisting of short-term memory, working memory, long-term memory, memory consolidation, procedural memory and declarative memory is prevented in the human following administration of the composition.
10 . The method of claim 1 , wherein the composition includes 1-amphetamine administered to the human at a daily dose of between about 1 mg 1-amphetamine and about 150 mg 1-amphetamine.
11 . The method of claim 1 , wherein the composition includes 1-methamphetamine administered to the human at a daily dose of between about 1 mg 1-methamphetamine and about 150 mg 1-methamphetamine.
12 . The method of claim 1 , wherein an impairment in at least one member selected from the group consisting of attention, executive function, reaction time, learning, information processing, conceptualization, problem solving and verbal fluency is prevented in the human following administration of the composition.